NO20091330L - Modifiseringer av kupredoxin avledede peptider samt fremgangsmater for bruk derav - Google Patents

Modifiseringer av kupredoxin avledede peptider samt fremgangsmater for bruk derav

Info

Publication number
NO20091330L
NO20091330L NO20091330A NO20091330A NO20091330L NO 20091330 L NO20091330 L NO 20091330L NO 20091330 A NO20091330 A NO 20091330A NO 20091330 A NO20091330 A NO 20091330A NO 20091330 L NO20091330 L NO 20091330L
Authority
NO
Norway
Prior art keywords
derived peptides
methods
peptides
pharmacological
cupredoxin
Prior art date
Application number
NO20091330A
Other languages
English (en)
Norwegian (no)
Inventor
Ananda Chakrabarty
Tapas Das Gupta
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of NO20091330L publication Critical patent/NO20091330L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20091330A 2006-09-11 2009-03-31 Modifiseringer av kupredoxin avledede peptider samt fremgangsmater for bruk derav NO20091330L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84338806P 2006-09-11 2006-09-11
PCT/US2007/078136 WO2008033820A2 (en) 2006-09-11 2007-09-11 Modifications of cupredoxin derived peptides and methods of use thereof

Publications (1)

Publication Number Publication Date
NO20091330L true NO20091330L (no) 2009-06-05

Family

ID=39184502

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091330A NO20091330L (no) 2006-09-11 2009-03-31 Modifiseringer av kupredoxin avledede peptider samt fremgangsmater for bruk derav

Country Status (14)

Country Link
US (2) US10005821B2 (de)
EP (1) EP2061487A4 (de)
JP (2) JP2010502765A (de)
KR (1) KR20090059148A (de)
CN (1) CN101600447A (de)
AU (1) AU2007296614A1 (de)
BR (1) BRPI0715027A2 (de)
CA (1) CA2663188A1 (de)
IL (1) IL197501A0 (de)
MX (1) MX2009002612A (de)
NO (1) NO20091330L (de)
RU (1) RU2009113562A (de)
SG (1) SG174108A1 (de)
WO (1) WO2008033820A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US9434770B2 (en) 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
US9598470B2 (en) * 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
US9968685B2 (en) * 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
EA200700813A1 (ru) 2004-10-07 2008-10-30 Ананда Чакрабарти Транспортирующие вещества, производные купредоксина и способы их применения
US8158574B2 (en) 2004-10-07 2012-04-17 Cdg Therapeutics, Inc. Compositions and methods to prevent cancer with cupredoxins
US8324153B2 (en) 2008-05-06 2012-12-04 New York Blood Center, Inc. Antiviral cell-penetrating peptides
JP2009502135A (ja) 2005-07-19 2009-01-29 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 血液脳関門を越えるための、および脳癌細胞内への輸送因子、並びにその使用方法
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
CA2665186A1 (en) * 2006-10-05 2008-04-17 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
CN101600728A (zh) * 2006-12-04 2009-12-09 伊利诺斯大学理事会 使用铜氧还蛋白和富含CpG的DNA治疗癌症的组合物和方法
MX2009008508A (es) * 2007-02-08 2010-04-21 Univ Illinois Composiciones y m?todos para prevenir el c?ncer con cupredoxinas.
CN103937705B (zh) * 2014-03-10 2016-03-16 赵晗 一株罕见无色杆菌及其在去除重金属离子中的应用
GB201700557D0 (en) * 2017-01-12 2017-03-01 Peptinnovate Ltd Novel peptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827934A (en) 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
US5972899A (en) 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
AU4678300A (en) 1999-04-30 2000-11-17 Slil Biomedical Corporation Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US6800437B1 (en) 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
KR100955974B1 (ko) 2001-02-15 2010-05-04 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 세포 사멸을 조절하는 세포독성인자
US7556810B2 (en) * 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
DE60332477D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
CN1506375A (zh) * 2002-12-12 2004-06-23 浙江养生堂天然药物研究所有限公司 具有广谱抗肿瘤作用的细菌蛋白天青蛋白及其用途和含有其的药物组合物
AU2003254065A1 (en) 2002-12-30 2004-07-29 Gryphon Therapeutics, Inc. Backbone anchored thioester and selenoester generators
EP1610813A4 (de) 2003-03-19 2009-07-01 Gen Hospital Corp KONFORMATIONSEINGESCHRÄNKTE PARATHORMONE MIT a-HELIX-STABILISATOREN
GB0321937D0 (en) 2003-09-19 2003-10-22 Univ Liverpool Nanoparticle conjugates and method of production thereof
EA200700813A1 (ru) * 2004-10-07 2008-10-30 Ананда Чакрабарти Транспортирующие вещества, производные купредоксина и способы их применения
WO2006062398A2 (en) 2004-12-07 2006-06-15 Applied Nanosystems B.V. Methods for the production and secretion of modified peptides
JP2009502135A (ja) * 2005-07-19 2009-01-29 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 血液脳関門を越えるための、および脳癌細胞内への輸送因子、並びにその使用方法

Also Published As

Publication number Publication date
US10005821B2 (en) 2018-06-26
JP2010502765A (ja) 2010-01-28
CN101600447A (zh) 2009-12-09
US10590177B2 (en) 2020-03-17
WO2008033820A8 (en) 2009-07-30
BRPI0715027A2 (pt) 2013-05-28
WO2008033820A3 (en) 2008-12-18
MX2009002612A (es) 2009-12-15
US20180319848A1 (en) 2018-11-08
RU2009113562A (ru) 2010-10-20
AU2007296614A1 (en) 2008-03-20
JP2014193886A (ja) 2014-10-09
EP2061487A4 (de) 2009-12-02
WO2008033820A2 (en) 2008-03-20
US20100267608A1 (en) 2010-10-21
CA2663188A1 (en) 2008-03-20
KR20090059148A (ko) 2009-06-10
EP2061487A2 (de) 2009-05-27
SG174108A1 (en) 2011-09-29
IL197501A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
NO20091330L (no) Modifiseringer av kupredoxin avledede peptider samt fremgangsmater for bruk derav
MX2019001198A (es) Activadores de moleculas pequeñas de funcion de la enzima parkin.
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
AU2018236800B2 (en) DNA-PK inhibitors
EP3736294A3 (de) Cd73-blockade
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
EA201190178A1 (ru) Замещённые нуклеозидные и нуклеотидные аналоги
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
DK2137301T3 (da) Adenovirus med mutationer i det endoplasmatiske reticulums retentionsdomæne for E3-19K-proteinet samt deres anvendelse ved cancerbehandling
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
EA201200559A1 (ru) Способы назначения терапии пирфенидоном
TN2013000325A1 (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
MX2009005300A (es) Combinacion de un inhibidor de acido desoxirribonucleico polimerasa-alfa y un inhibidor de una cinasa de punto de verificacion para trastornos proliferativos.
WO2010011343A3 (en) Methods for treating viral disorders
IN2012DN02471A (de)
PH12014501937A1 (en) Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
EA201390217A1 (ru) Способы лечения алкогольной интоксикации, расстройств, связанных с употреблением алкоголя, и злоупотребления алкоголем, которые включают введение дигидромирицетина
MX2008002294A (es) Derivados de pirimidina sustituida.
WO2013016278A3 (en) Modulators of antiviral signaling pathways and therapeutic uses thereof
IN2012DN00592A (de)
WO2010096681A3 (en) Modifications of cupredoxin derived peptides and methods of use thereof
WO2010011700A3 (en) Treatment of cancers characterized by chromosomal rearrangement of the nut gene

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application